Senior Principal Scientist

David Tung, Ph.D.

***** ********* **.,

Wildwood, MO 63005

Home: 303-***-**** (cell)

Personal Cell: 303-***-****

email: **********@*******.***

______________________________________________________________________________

EDUCATION

August 1995

Ph.D. - BIOMEDICAL ENGINEERING

University of California, San Diego.

Dissertation Title: The Role of Neutrophils in Parenchymal Cell Death During an Acute Inflammatory Reaction in the Mesentery.

September 1991

M.S. - BIOMEDICAL ENGINEERING

University of California, San Diego.

June 1990

B.S. - BIOMEDICAL ENGINEERING

University of California, San Diego.

PROFESSIONAL TRAINING COURSES

Fall 1998 Pharmacology and Drug Discovery - PERI

Spring 1999 Flow Cytometry and Operator's training course for EPICS XL and EXPO - Coulter

Summer 2001 Regulatory Affairs Training - IND and NDA phase - DIA

PROFESSIONAL AFFILIATIONS

Member of Inflammatory Research Association.

Member of Osteoarthritis Society International.

Member of CSM/NASA Biomaterials Research Consortium

Member of Strategic Advisory Board for NIH Bioengineering Research

Partnership, Bone Tissue Engineering Center, Carnegie Mellon University.

PROFESSIONAL EXPERIENCE

2006 to April 2009

Senior Principal Scientist, Translational Pharmacology, Pfizer Inc., Chesterfield, MO

a) Disease Modifying Osteoarthritis Drug Discovery Group (DMOAD)

• Leader for an intra articularly delivered growth factor project. Plan and coordinate effort from safety, legal, marketing, formulation departments and corporate partners to meet project timeline, and generate critical data to support Go/ No Go decisions. Manage external studies and collaborations to ensure timely transfer of technical information and chemical matters.

• Evaluate and develop novel sustained release formulations, and other novel retention technologies to enable intraarticular delivery of DMOAD drugs, and minimize the frequency of injection.

• Validate and utilize novel 3-D near-infra-red (nIR) imaging technique to address questions regarding PK and formulation retention in the joint.

• Design and execute in vivo studies to evaluate anti-catabolic and anabolic compounds in rodent models of osteoarthritis.

• Design and implement strategies to evaluate anatomical MRI and dGEMRIC for pre-clinical application, and evaluate the translatability to clinical use.

b) Allergy and Respiratory Group (A&R)

• Champion for novel technologies - established and validated pulmonary mechanics measurement and aerosol delivery systems to support the A&R drug discovery effort. Explored potential application of new imaging technologies for evaluating the PK and efficacy profiles of inhale drug entities.

• Member of due diligence team - collaborated with colleagues in legal, strategic alliance, toxicology and other therapeutic areas to evaluate licensing opportunities, and new technologies including antisense and siRNA. Performed due diligence visits to audit potential partners. Nominated and evaluated novel targets for development and POC studies.

• Designed and executed in vivo studies in support of the A&R drug discovery effort.

• Organizer of the Pfizer St. Louis A&R Research Community (STARRC) scientific and technology exchange – ensured ground breaking scientific and technology discoveries were communicated to colleagues from different departments.

• Involved in the design of the new A&R vivarium facility at the Chesterfield site to support viral exacerbation models of COPD.

• Harmonized protocols and SOPs with Pfizer’s Sandwich, UK site. Ensured accurate transfer of technical expertise to the Sandwich site, and continuity of projects during the re-organization.

• Member of Pfizer’s scientific education out reach program to project Pfizer’s corporate image and philosophy.

2005 to 2006

Associate Director, Inflammation and Allergic Disease Research

Sirna Therapeutics, Boulder, CO

• Designed and implement strategy to demonstrate mechanism based efficacy for siRNA.

• Worked with IACUC to establish SOP for experimental procedures. Validated in vivo models of inflammation.

• Trained personnel on in vivo techniques and the operation of equipment for lung function measurements.

• Performed experiments to evaluate efficacy, and characterized PK and toxicology profile of modified siRNA molecules.

• Characterized the physical behavior of aerosolized siRNA molecules (MMAD and GSD).

• Member of transition team to establish new facility in the Sirna headquarter in San Francisco.

• Prepared report for Board of Directors and corporate partners. Made presentations to corporate partners at due diligence trips and at public meetings to increase the visibility of the RNAi technology.

• Responsible for the design and compilation of data package to support a corporate strategic alliance with GSK (total mile stone payment in excess of $700 million). Generated data package to support the sale of Sirna to Merck for $1.2 billion.

2001 to 2005

Assistant Director, In Vivo Modeling Group

Antisense Drug Discovery, Isis Pharmaceuticals, Carlsbad, CA.

• Managed and trained the Isis in vivo inflammation/oncology team.

• Validated in vivo models in arthritis, osteoarthritis, asthma and oncology.

• Worked closely with Dr. Tomas Dam of Aarhus, Denmark to evaluate the application of antisense oligonucleotide in the treatment of psoriasis in the PP SCID mouse xenograft model.

• Established novel drug delivery techniques including aerosol delivery of antisense oligonucleotides to the lungs of rodent and primate, and circumventing the blood brain barrier with novel delivery techniques.

• Performed PoC studies to demonstrate antisense efficacy in xenograft models. The data I generated for Survivin and eIF4E triggered an extension of Isis’s collaboration with Eli Lilly. These two projects are currently in clinical development.

• Set up SOP and IACUC approved protocols for in vivo experimental procedures, and provided necessary training for associates.

• Coordinated effort with PK and toxicology groups to support drug discovery effort in arthritis, asthma, oncology and psoriasis.

• Managed external studies in domestic and foreign contract facilities. Provided guidance for junior associates in their career development.

• Communicated internal data and analysis to the Isis corporate partners, which include ATL, Novosom AG, CDC, and Eli Lilly.

1999 to 2001

Research Scientist II/Assistant Project Manager

Chiron Corporation, Department of Pharmacology, Emeryville, CA.

• Managed preclinical pharmacology projects in inflammation, osteoarthritis, orthopedics and CNS indications. Duties included design and execution of in vivo experiments, and management of multiple external collaborations with contract labs and academic institutions.

• Evaluated the efficacy of various biologics in the PP and PN SCID mouse xenograft models of psoriasis in collaboration with Dr. Tomas Dam of the Aarhus Metropolitan Psoriasis Treatment Center, and Dr. Eugene Farber of the Psoriasis Research Institute.

• Project leader for the development of second generation Betaseron product, and development of proprietary drug delivery platform for circumventing the blood brain barrier.

• Worked closely with scientists and attorneys in various departments to formulate clinical and preclinical strategies, took part in the preparation of partnering packages, IND and IB, and facilitated the submission of patent application.

• Head of a committee that evaluated external drug requests and collaborations.

• Project involvement: IGF-I, Betaseron, and two proprietary preclinical projects.

1998 to 1999

Research Scientist, Department of Pharmacology

Celera (Axys) Pharmaceuticals Inc., South San Francisco.

• Designed and executed in vivo experiments to evaluate proprietary immunomodulatory compounds, and supervised up to four research assistants.

• Developed in vitro cell based antigen presentation assay, and in vivo inflammation models.

• Participated in the screening of oncology compounds.

• Chairman of IACUC. Revised and approved in vivo protocols, and monitored the standard of animal use and care. Set up standard operating procedures for animal handling.

1995 to 1998 Postdoctoral Fellow

Supervisors: Dr. Peter A. Ward, Dept. of Pathology, University of Michigan Medical School, and Dr. Denis J. Schrier, Dept. of Immunopathology, Parke-Davis Pharmaceutical Research Division of Warner-Lambert Company.

Research Focus: The role of Th1 and Th2 cytokines and neurogenic mechanisms in disease propagation and soft tissue metabolism in various animal models of arthritis. Responsibilities included testing of proprietary compounds, development of novel animal models, performing aseptic surgery on rabbits, antibody production, isolation and quantification.

1990 to 1995 Research Assistant

Microcirculation Laboratory, Institute for Biomedical Engineering, University of California, San Diego.

Extensive laboratory research involving the kinetic relationship between activated neutrophils and parenchymal cells during acute inflammatory reactions in the mesentery. Modeling of leukocyte transendothelial diapedesis in post-capillary venules and mechanisms behind the related cell death.

Fall 1993 Graduate Consultant

Institute For Biomedical Engineering, University of California, San Diego.

Fall 1990 Teaching Assistant

Institute for Biomedical Engineering, University of California, San Diego.

1988 to 1990 Research Associate

Malcolm and Dorothy Coutts Institute for Joint Reconstruction and Research, San Diego, CA.

Conducted testing of biomechanical properties of ligaments and tendons on Instron material testing machine.

1988 to 1990 Laboratory Assistant

Division of Orthopedics and Rehabilitation, Department of Surgery, University of California, San Diego.

Evaluated the effect of continuous passive motion on healing of lacerated flexor tendon.

1988 to 1990 Research Associate

Orthopedic Bioengineering Laboratory, San Diego VA Medical Center, San Diego, CA.

Project leader responsible for design and evaluation of prototype laser micrometer data acquisition system for measuring cross sectional shape and area of ligaments

TECHNICAL SKILLS

*In Vivo Models

Arthritis/Local Ankle Inflammation

- Streptococcal Cell Wall Induced Reactivation Arthritis

- Streptococcal Cell Wall Induced Chronic Arthritis

- Collagen Induced Arthritis

- Adjuvant Induced Arthritis

- IL-1 induced local TNF-α production in the ankle joint

- Medial Meniscus Tear Model in Rats

- Monosodium Iodoacetate Induced Osteoarthritis

- Meniscectomy Induced Osteoarthritis in Rabbits

Asthma Models

- OVA Induced Acute Pulmonary Hyperreactivity

- OVA Induced Chronic Pulmonary Hyperreactivity

- Ascaris Induced Airway Hyperreactivity Model in cynomogous monkeys

Oncology Models

- Lewis Lung Carcinoma Model

- Orthotopic tumor model: mammary fat pad

- Xenograft Models: PC-3, U87, MDA-MB-231

Neuroscience surgeries and techniques

- Dorsal rhizotomy

- Drug delivery to dorsal horn via implanted microdialysis fiber

- Laminectomy

- Implantation of osmotic pump for continuous drug delivery

- Intrathecal cannulation

- Von Fry’s Filament

- Hargreave’s Apparatus for thermal hyperalgesia measurements

- Randall-Selitto technique for nociceptive quantification

Menisectomy of the rabbit knee joint

(Trained and Certified by Parke-Davis Pharmaceutical Research for Aseptic

Surgery)

Imaging Techniques:

Intravital and fluorescent microscopy

Surgical procedures involved:

- Mesentery preparation

- Spinotrapezius muscle preparation

- Gracilis muscle preparation

Cremaster muscle preparation

Time lapse video microscopy

3D NIR (near infra red) fluorescent Topographic microscopy

Drug delivery pathways:

- Intraperitoneal, intravenous (rat tail vein and rabbit ear vein), intramuscular, intraarticular, and intrathecal injections

- Aerosol delivery of nebulized formulations to rodent and primate (calculation of dosing duration, dose solution concentration, and design of dosing equipment)

- Proprietary intranasal delivery (circumvent the blood brain barrier for direct CNS delivery).

- Oral gavage

- Venous and arterial cannulation

Various blood collection techniques

Biomaterial Implantation

Lavage of ankle and knee joints and lungs

Operation of Buxco Ankle Edema Plythesmometer

Operation of Buxco Full Body Plythesmometer for Lung Function Measurements

Operation of SciReq Flexivent System for Invasive Measurement of Lung Function

Operation of Incapacitance Tester for Weight Bearing Measurements (OA or RA end point)

In vitro techniques:

*Transmission Electron Microscopy and sample preparation

*Scanning Electron Microscopy and sample preparation

*Northern blot (RNA extraction and quantification)

*ELISA

*Histological sample preparation and analysis

*Cell Culture Techniques

Related laboratory skills:

*Excellent verbal, written communication, and mediation skills

*Operation of Instron Material Testing Machine

*Operation of various transducers for measuring strain, displacement, and stress.

*Biometry

*Computer Languages: HTML, Basic, Fortran

PATENTS:

Karras J, Crosby J, Tung D, Geary R, Monia B, and Gregory S. Compositions and the Use of Interleukin-4 Receptor-alpha Antisense Oligonucleotide.

Jamison S., Tung D., Vargeese C., and Richards I. Compositions and Formulation of siRNAs for Delivery to Specific Cell Types in the Respiratory Tract.

ABSTRACTS:

Whiteley L.O, Dullea R., Tung, D., Singh, S., Hunt, S. RNAi Applications to Assess Target Mechanism and Safety: From In-vitro to In-vivo. 2008 RNAi Based Therapeutics Meeting; June 10-11, 2008, San Francisco, CA.

Liachenko S., Tung D., Sunyer, T., Settle, S.L., Bocan T., Xie Z.S. The application of MRI to a preclinical model of osteoarthritis. ISMRM-ESMRMB Joint Annual Meeting, 19-25th May, 2007, Berlin, Germany

Prévot A., Mosig D., Julita M., Tung D.K. and Guignard J.-P. Insulin-like growth factor-1 (IGF-1) improves the hypoxemia-induced acute renal vasomotor nephropathy in the newborn rabbit. 40th Annual Meeting of the European society of Pediatric Nephrology. Palermo, Italy. October 7-10, 2006.

Jamison S., Tung D., Shadel T., Vargeese C., Pavco P., Hartsough K., Gomez A., Dickinson B., Wang W., Chen T., Zhang Y., Vagle K., and Richards I. Formulation of siRNAs for delivery to specific cell types in the respiratory tract. Keystone Conference, Allergy, Allergic inflammation and asthma, Breckenridge April 6-11, 2006.

Tung D., Hartsough K., Gomez A., Shadel T., Wang W., Chen T., Zhang Y., Vagle K., Vargeese C., and Richards I. Cytokine induction and lung inflammation induced by siRNA is abrogated by chemical modification. Keystone Conference, Allergy, Allergic inflammation and asthma, Breckenridge April 6-11, 2006.

Richards I., Hartsough K., Dickinson B., Gomez A., Jamison S., Shadel T., Lockridge J., Pavco P., Wang W., Chen T., Vargeese C., Wohlford-Lenane C., McCray P., Tung D. Chemical Modification and Formulation of Short Interfering RNA (siRNA) for Local Delivery to the Lungs. Keystone Meeting (RNAi and Related Pathways), January 26 - 31, 2006, Vancouver, British Columbia, Canada.

Tung D., Gomez A., Hartsough K., Jamison S., Shadel T., Dickinson B., Vargeese C., Pavco P., Richards I. Effect of stabilized, formulated IL-4Rα siRNA on ovalbumin-induced lung inflammation and airway hyperresponsiveness in sensitized mice. Keystone Meeting (RNAi and Related Pathways), January 26 - 31, 2006, Vancouver, British Columbia, Canada.

Prévot A,. Mosig D., Julita M., Tung D., and Guignard J.-P. Insulin-like growth factor-I improves the state of renal failure induced by hypoxemia in the newborn rabbit. Annual meeting of the French Society for Pediatric Nephrology (SNP), with the participation of the Dutch Society for Pediatric Nephrology. November 17-19, 2005, Amsterdam, Netherlands..

Karras J.G., Crosby J.R., Tung D., Guha M., Miller D., Kowalski D., Osgood T.L., Gaarde W., Monia B.P., and Gregory S.A. Inhaled TNF-alpha antisense oligonucleotide inhibits lung inflammation and airway hyper-responsiveness in mouse models of asthma. GTCbio Cytokines and Inflammation Meeting, January 27-28, 2005, San Francisco, CA

Guha M., Crosby J.R., Arberg C., Luther D., Brown H., Fan A.X., Osgood T.L., Tung D., Gaarde W., Monia B.P., Karras J.G. and Gregory S.A. An aerosolized IL-4R alpha antisense oligonucleotide (ASO) reduces target gene expression on epithelial and inflammatory cells and suppresses the pulmonary response to allergen in mice. 9th International Inflammation & Immune Diseases Drug Discovery & Development Summit, March 14-15, 2005, Philadelphia, PA

Karras J.G., Guha M., Crosby J.R., Tung D., Miller D., Kowalski D., Arberg C., Lin D., McKay K., Osgood T.L., Monia B.P., and Gregory S.A. Anti-inflammatory activity of inhaled p38α-MAPK antisense in mouse models of asthma. Strategic Research Institute’s 9th International Inflammation & Immune Diseases Drug Discovery & Development Summit, March 14-15, 2005, Philadelphia, PA

Miller D.A., Crosby J.R., Tung D., Kowalski D., Arberg C., Lin D , Osgood TL , Gaarde WA , Monia BP , Karras JG , and Gregory SA. Local delivery of TARC antisense oligonucleotides suppresses allergen-induced pulmonary inflammation and airway hyperresponsiveness in mice. FASEB, April 2-6, 2005, San Diego, CA

Gaarde W.A. , Guha M., Crosby J., Miller D., Kowalski D., Tung D., Arberg C., Lin D., McKay K., Osgood T.L., Monia B.P., Karras J., and Gregory S.A. Antisense oligonucleotides targeting p38 alpha reduce ovalbumin-induced pulmonary inflammation in mice. American Thoracic Society Annual Meeting, May 20-25, 2005, San Diego, CA

Crosby J.R., Tung D., Guha M., Luther D., Kowalski D., Osgood T.L., Gaarde W., Monia B.P., Karras J. and Gregory S.A.. Inhaled TNF alpha antisense oligonucleotide inhibits lung inflammation and airway hyper-responsiveness in a mouse model of chronic asthma. American Thoracic Society Annual Meeting, May 20-25, 2005, San Diego, CA

Crosby J.R., Tung D., Guha M., Kowalski D., Luther D., Arberg C., Lin D., Osgood T.L., Gaarde W., Lofthouse S., Monia B.P., Karras J.G.and Gregory S.A.. Aerosol delivery of VLA-4 specific antisense oligonucleotides inhibit airway inflammation and hyperresponsiveness in mice. American Thoracic Society Annual Meeting, May 20-25, 2005, San Diego, CA

Crosby J., Tung D., Guha M., Arberg C., Luther D., Brown H., Fan A.X., Osgood T., Gaarde W., Brett P. Monia B.P, Karras J., Gregory S.A..Suppression of allergen-induced airway inflammation and hyper-responsiveness by a CD86 ASO. IBC Inflam Drug Discovery 2004.

Guha M., Xu Z., York-DeFalco C., Tung D., Hung G., Arberg C., Lanting L., Li S., Cai Q., Natarajan R., and Monia B.P. Antisense oligonucleotide to connective tissue growth factor (CTGF) shows promise in blocking disease progression in both Type I and Type II models of diabetic nephropathy. SA-FC035, American Society of Nephrology, St Louis, Missouri 2004

Tung D., Gregory S., Guha M., Miller D. A., McKay K., Gaarde W.A., Monia B.P., Wong W-SF., Crosby J.C., Karras J. Local administration of antisense inhibitor of p38α MAPK suppresses allergen induced lung inflammation and airway hyperreactivity in mice. 12th International Conference, Inflammation Research Association 2004.

Guha M., Crosby J.C., Tung D., Luther D. A., McKay K., Arberg C., Gaarde W.A., Kowalski D., Monia B.P., Karras J., Gregory S. Molecular and cellular mechanisms underlying airway inflammation and hyperreactivity in a murine model of asthma. 12th International Conference, Inflammation Research Association 2004.

Crosby J.C., Arberg C.C., Mercer K., Witchell D., Gregory S., Tung D.K.-L. The effect of B7.2 antisense oligonucleotide on ovalbumin induced airway hyperreactivity. 6th World Congress on Inflammation 2003.

Guha M., Crosby J.C., Luther D. A., McKay K., Arberg C., Gaarde W.A., Cooper S., Monia B.P., Tung D., Karras J., Gregory S. Local Delivery of a B7.2 specific antisense oligonucleotide inhibits airway inflammation and hyperresponsiveness in mice. Inflammation Research. Vol 52 S85. 2003.

Magill C., Bass K., Underwood S., Vitali N., Tung D., Biroc S., Tam B., Gosink L., Jones C., Allen E., Aldous D., Palmer J. Cysteine proteases in antigen presentation and inflammation. 11th International Conference, Inflammation Research Association 2002.

Tung, D. K.-L., Taylor, C., Vasko, M. R., Gilbertsen, R.B., Dyer, R., Ward, P. A., and Schrier, D. J. The anti inflammatory effect of two novel analgesic compounds: Gabapentin and Pregabalin (CI-1008) in streptococcal cell walls induced arthritis. Keystone Symposia on Rheumatoid Arthritis, 1998.

Schrier, D. J., Schimmer, R. C., Flory, C. M., Dykens, J., Laemont, K., Jacobson, P. B., Tung, D. K.-L., and Ward, P. A. The role of chemokines, cytokines and adhesion molecules in arthritis induced with streptococcal cell walls. Keystone Symposia on Molecular and Cellular Biology, 1997.

Baginski, T. J., Tung, D. K.-L., Dykens, J. A., Schrier, D. J. The role of hydroxyl radical in rodent model of arthritis. FASEB 1997.

Tung, D. K.-L., Ward, P. A., Schimmer, R. C., Warner, R., Schrier, D. J. The role of Th1 and Th2 cytokines in the SCW induced reactivation arthritis model. Keystone Symposia on Molecular and Cellular Biology, 1997.

Tung, D. K.-L., Ward, P. A., Schrier, D. J. Comparison of soft tissue metabolism in different animal models of arthritis. FASEB, 1997.

Tung, D. K.-L., Schmid-Schönbein, G. W., Zweifach, B. W. Topographical distribution of parenchymal cell death during acute inflammatory reaction in the mesentery. Microcirculatory Society Annual Meeting, 1995.

Tung, D. K.-L. Leukocyte diapedesis in rat mesentery and resulting vascular damage during acute inflammatory reaction. Proceedings of Bioengineering Graduate Student Symposium. University of California, San Diego. 1994.

Ohashi, K. L., Tung, D. K.-L., Zweifach, B. W., Schmid-Schönbein, G.W. Mechanism of transendothelial and interstitial neutrophil migration. Proceedings of 18th European Conference on Microcirculation, 1994.

Tung, D. K.-L., Schmid-Schönbein, G. W., Zweifach, B. W. Transendothelial pathways during neutrophil diapedesis in rat mesentery. FASEB J. 8:A321,

1994.

Tung, D. K.-L. Leukocyte transendothelial emigration during inflammatory reaction. Proceedings of Bioengineering Graduate Student Symposium. University of California, San Diego. 1993.

Ohashi, K.L., Tung, D. K.-L., Wilson, J., Schmid-Schönbein, G.W. Kinetics of neutrophil migration across rat mesenteric venules using time-lapse video photography. FASEB J, 7:M127, 1993.

Ohashi, K. L., Tung, D. K.-L., Lee, D., DeLano, F.A., Schmid-Schönbein, G.W. Transendothelial migration of granulocytes in rat mesentery venules. Proceedings of Fifth World Congress for Microcirculation. 1992.

Takai, S., Woo, S. L.-Y., Tung, D. K.-L., Gelberman, R. H. The effects of frequency and duration of controlled passive mobilization on tendon healing. Transactions of the 37th Annual Meeting Orthopedic Research Society. Volume 16-Section 1. 1991.

PUBLICATIONS:

Schoell A., Heyde B., Weir D., Chiang P., Hu Y., Tung D. The Development of a Novel Euthanasia Method for Mice in Support of Rapid Time Course Pulmonary Pharmacokinetic Studies. Journal of the American Association for Laboratory Animal Science. In print. April 2009

Chiang P.C., Alsup J.W., Hu Y., Heyde B.R., Lai Y., Tung D. Evaluation of Aerosol Delivery of Nano-suspension for Preclinical Pulmonary Drug Delivery. Nanoscale Research Letters. In print. 2009

Prévot A., Julita M., Tung D.K., and Mosig D. Beneficial Effects of Acute Administration of Insulin-Like Growth Factor-1 (IGF-1) on Hypoxemia-Induced Renal Dysfunction of the New Born Rabbit. Pediatric Nephrology. Epub. 2008

Thorne, R. G, Fawcett J.R., Ala T.A., Tung D.K-L., Frey, W. Delivery of interferon-beta to the monkey nervous system following intranasal administration. Neuroscience. 2008 Mar 27; 152(3):785-97. Epub 2008 Jan 16.

Karras J, Crosby J, Guha M, Tung D, Miller D, Gaarde W, Geary R, Monia B, and Gregory S. Anti-inflammatory Activity of Inhaled Interleukin-4 Receptor-alpha Antisense Oligonucleotide in Mice. Am J Respir Cell Mol Biol. 2007 Mar; 36(3):276-85.

Guha M, Xu ZG, Tung D, Lanting L, Natarajan R. Specific down-regulation of connective tissue growth factor attenuates progression of nephropathy in mouse models of type 1 and type 2 diabetes. FASEB J. 2007 Oct; 21(12):3355-68. Epub 2007 Jun 6.

Crosby JR, Guha M, Tung D, Miller DA, Bender B, Condon TP, York-DeFalco C, Geary RS, Monia BP, Karras JG, Gregory SA. Inhaled CD86 antisense oligonucleotide suppresses pulmonary inflammation and airway hyper-responsiveness in allergic mice. J Pharmacol Exp Ther. 2007 Jun; 321(3):938-46. Epub 2007 Mar 26.

Prévot A., Mosig D., Julita M., Tung D.K. and Guignard J.-P. Insulin-like growth factor-I (IGF-I) improves the hypoxemia-induced acute renal vasomotor nephropathy in the newborn rabbit. Pediatric Nephrology 2006; 21:1507.

Schrier, D.J., Schimmer, R.C., Flory, C.M., Tung, D. K.-L., Ward, P.A. The role of chemokines, cytokines in a reactivation model of arthritis in rats induced by injection with streptococcal cell walls. Journal of Leukocyte Biology, Mar , 63(3), p 359-363, 1998.

Leyshon A. M., Chouinard L., Aukerman S., Tung D. K.L. The effect of IGF-I on meniscectomy induced osteoarthritis in rabbit. In review by the legal department of Chiron Corporation (Novartis).

Schimmer, R.C., Schrier, D.J., Flory, C.M., Dykens, J., Tung, D. K.-L., Jacobson, P. B., Friedl, H.P., Conroy, M.C., Schimmer. B. B., Ward, P.A. Streptococcal cell walls induced arthritis: Requirements for neutrophils, P-selectin, ICAM-1 and MIP-2. Journal of Immunology, Oct. 159(8): 4103-8, 1997

Schimmer, R. C., Schrier, D. J., Flory, C. M., Schimmer, B. B., Dykens, J., Tung, D. K.-L., Jacobson, P. B., Friedl, H. P., Conroy, M. C., Ward, P. A. Streptococcal wall-induced arthritis: Requirements for neutrophils, P-selectin, ICAM-1 and MIP-2. Journal of Immunology, Oct. 159(8), p4103-4108, 1997.

Tung, D. K.-L. The role of neutrophils in parenchyma cell death during an acute inflammatory reaction in the mesentery. Ph. D. Thesis, University of California, San Diego, (1995). UMI: 96-01,750. Library of Congress, Reg. No. TX 4-274-135.

Tung, D. K.-L., Bjursten, L. M., Zweifach, B. W., Schmid-Schönbein, G. W. Leukocyte contribution to parenchymal cell death in an experimental model of inflammation. Journal of Leukocyte Biology. Vol. 62, No. 2, 163-175, Aug. 1997.

Ohashi, K.L., Tung, D. K.-L., Wilson, J., Schmid-Schönbein, G.W. Transvascular and interstitial migration of neutrophils in rat mesentery. Microcirculation, Vol. 3, No. 2, 199-210, 1996.

Takai, S., Woo, S. L.-Y., Tung, D. K.-L., Gelberman, R. H. The effects of frequency and duration of controlled passive mobilization on tendon healing. Journal of Orthopedic Research, Sept. 9(5):705-13, 1991.

Pfizer Osteoarthritis Manuscripts in Preparation:

Liachenko S., Sunyer T., Settle S.L., Branson L.F., Tung D., Bocan T. MRI as a Measure of Lesion Progression in a Rodent Model of Osteoarthritis.

Sunyer T., Tung D., Settle S.L., Branson L.F., Vickery, L.E., Murphy, M. K., Aguiar, D.J. Pharmacokinetic and Pharmacodynamic Profiles of Intraarticularly Injected CD-RAP.

Tung D., Sunyer T., Settle S.L., Branson L.F., Turner, S., Aguiar, D.J. Anabolic Effects of Intraarticularly Injected hGH in a Rodent Model of Osteoarthritis.

Branson L.F., Sunyer T., Settle S.L., Vickery, L.E., Aguiar, D.J., Murphy, M. K., Tung D. Correlation of Biomarkers and Histological Endpoints in the Rodent Medial Menisectomy Model of Osteoarthritis.

Svedrup, F., Sunyer T., Settle S.L., Branson L.F., Vickery, L.E., Tung, D., Murphy, M. K., Hortz, K. Sucrose Acetate IsoButyrate Extended Release (SABER) Formulation Enhanced Pharmacokinetic and Pharmacodynamic Profiles of Intraarticularly Injected hGH in Beagle Dogs.

Lyon, D., Boras, W., Tung D., Sunyer T., Settle S.L., Branson L.F., Murphy, M. K., Morgan M. The Development of a Hyaluronic Acid Polymerizing Sustained Release Formulation for the Intraarticular Delivery of Anabolic Agents.

Contact this candidate